![](https://cdn.statically.io/img/static01.nyt.com/images/2024/07/01/multimedia/00AlzheimersDrug-01b-kzjt/00AlzheimersDrug-01b-kzjt-thumbWide.jpg?quality=75&auto=webp&disable=upscale)
New Drug Approved for Early Alzheimer’s
The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.
By Pam Belluck
I cover a range of subjects, including reproductive health, long Covid, brain science, neurological disorders, mental health and genetics. My stories aim to depict the reality of people’s experiences with health and medicine, reflecting its complexity, subtlety, unpredictability and individuality. I’m interested in how developments and challenges in illness and medical science affect patients, families and communities. I’ve written about postpartum depression and infectious diseases like Covid-19, Ebola and Zika. I also cover the intersection of policy and health, such as abortion and contraception. And I’ve done investigative reporting on controversial issues, such as the Alzheimer’s drug Aduhelm. I also enjoy writing about lighter topics, including a cat that got lost near the Daytona Speedway but somehow navigated 200 miles home two months later and the discovery of the world’s oldest leather shoe (size 7, right foot, preserved for 5,500 years in sheep dung).
I’ve reported throughout the United States and in Asia, South America, Europe and Africa. After graduating from Princeton with a degree in international relations, I became a freelance foreign correspondent in the Philippines, primarily for The San Francisco Chronicle, then worked in Atlanta and Philadelphia.
At The Times, I served as bureau chief in the Midwest and New England, then received a yearlong fellowship to study science at M.I.T. and Harvard and began covering medical subjects.
I’m honored that my work on Ebola with six colleagues won a Pulitzer Prize for international reporting and other awards. I contributed, with many colleagues, to coverage of Covid-19, which earned The Times a Pulitzer for public service. Other honors include the Victor Cohn Prize for Excellence in Medical Science Reporting and being selected for The Best American Science Writing. My book “Island Practice,” about an unusual doctor, has been optioned for television. I’m also a jazz flutist and once sang a Sinatra song to get a story.
My colleagues at The Times and I are committed to upholding the standards of integrity outlined in our Ethical Journalism Handbook. I work hard to ensure that my stories are accurate and fair. It’s very important to me to treat people with respect and empathy. I explain the story I am working on and encourage people to feel comfortable asking me questions about the process. I honor commitments I make to sources. I ask for evidence and documentation, and I believe that journalism should hold institutions and powerful figures to account for their actions. I do not accept gifts, money or favors from those who are involved in a story I’m working on. I do not participate in political causes or make political donations. I make every effort to understand issues from multiple angles and perspectives.
Email: Pam.Belluck@nytimes.com
X: @PamBelluck
WhatsApp: Email or message me for WhatsApp number
Signal: Email or message me for Signal number
LinkedIn: Pam Belluck
Anonymous tips: nytimes.com/tips
The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.
By Pam Belluck
Though the Supreme Court ruled upheld access to mifepristone, the case is likely to be revived by three Republican-led states as the plaintiffs.
By Pam Belluck
This was featured in live coverage.
By Abbie VanSickle
Plus, a dispatch from the U.S.-Mexico border.
By Tracy Mumford, Pam Belluck, Edgar Sandoval, Davis Land and Jessica Metzger
The modest benefits of the treatment, donanemab, made by Eli Lilly, outweigh the risks, the panel concluded unanimously.
By Gina Kolata and Pam Belluck
The National Academies said the condition could involve up to 200 symptoms, make it difficult for people to work and last for months or years.
By Pam Belluck
New research shows that people who develop dementia often begin falling behind on bills years earlier.
By Ben Casselman
The legislation would make possession of the drugs without a prescription a crime in Louisiana, punishable with jail time.
By Emily Cochrane and Pam Belluck
A bill that is expected to pass would impose prison time and thousands of dollars in fines on people possessing the pills without a prescription.
By Pam Belluck and Emily Cochrane
People with two copies of the gene variant APOE4 are almost certain to get Alzheimer’s, say researchers, who proposed a framework under which such patients could be diagnosed years before symptoms.
By Pam Belluck